Salk Researchers Uncover Key GLP-1 Mechanism for Pancreatic Health
Salk Institute researchers have identified a key molecular mechanism through which GLP-1 drugs enhance the health of pancreatic beta cells. These drugs are recognized for their roles in treating diabetes, promoting weight loss, and improving cardiovascular health.
The study, published in Proceedings of the National Academy of Sciences on March 4, 2026, focused on how GLP-1 drugs improve beta cell viability and stress resistance. Researchers screened for regulatory proteins that activate beneficial gene programs during prolonged GLP-1 use.
They identified Med14, a protein within the Mediator complex, as crucial for enabling the GLP-1-dependent changes in gene expression that lead to pancreatic health benefits.
Understanding GLP-1 Drugs
GLP-1 receptor agonists mimic a natural hormone, glucagon-like peptide-1, which regulates blood sugar by promoting insulin secretion from pancreatic beta cells. A key difference is that artificial GLP-1 drugs remain in the body longer than the natural hormone. This extended presence is suspected to contribute to the broader benefits observed beyond immediate blood sugar regulation.
Med14's Role in Pancreatic Health
The research team investigated the molecular changes occurring with long-term GLP-1 drug exposure. They found that GLP-1 activation leads to a specific chemical modification, phosphorylation, of Med14. This protein is a subunit of the Mediator complex, which broadly regulates gene expression.
To confirm Med14's role, researchers mutated the protein to be resistant to phosphorylation. In both a Med14 mutant pancreatic beta cell line and a Med14 mutant mouse model, the gene expression patterns associated with prolonged GLP-1 drug exposure disappeared. Conversely, when Med14 functioned normally, beneficial gene programs were activated, enhancing pancreatic beta cells' growth and ability to manage sugar-rich environments.
Future Research and Implications
While these experiments were not conducted in humans, some genes regulated by Med14 phosphorylation are known to be associated with type 2 diabetes susceptibility in humans. Researchers anticipate further studies to validate these findings in human tissues and explore Med14's role in other cells and organs, such as fat tissue. They also aim to determine if other drugs or hormones can activate similar genetic pathways to GLP-1.
The research was supported by grants from the National Institutes of Health, Breakthrough T1D, Paul F. Glenn Foundation for Biology of Ageing Research, Clayton Foundation for Medical Research, and Leona M. and Harry B. Helmsley Charitable Trust. Additional authors included Jungting Yu, K. Garrett Evensen, Edmund Pakhlevanyan, and April Williams from Salk.